Proteomic analysis of meningioma of different grades identifies potential therapeutic targets and biomarkers
PXD007044, PXD007125, PXD007073Dunn et al., 2019
Proteomic profiling: Diamandis lab and Hanemann lab cohorts
Two independent proteomics efforts stand out: PXD012923 (Papaioannou, Diamandis et al., Neuro-Oncology 2019) profiled meningiomas by clinically-distinct molecular pattern; PXD007044 (Dunn, Hanemann et al., EBioMedicine 2019, consolidated from three duplicate PRIDE submissions, PXD007044/PXD007125/PXD007073) discovered differential expression of NEK9, HK2, and SET across meningioma grades. Neither has RNA-seq or methylation companions in this registry yet, making them currently "orphan" modalities for their respective cohorts, a candidate target for future cross-referencing if the underlying patient IDs can be matched to other repositories.
Overview
- Modality
- Proteomics (bulk MS)
- Sample count
- Not reported
- Patient count
- Not reported
- Institution
- University of Plymouth
- Corresponding author
- Jemma Dunn / C. Oliver Hanemann
- Platform
- LTQ Orbitrap Velos
- Access type
- open
- Tissue preservation
- fresh_frozen
- WHO edition
- Not reported
Cohort detail
- Grade breakdown
- Not reported
- Sex distribution
- Not reported
- Age distribution
- Not reported
- Anatomic location
- Not reported
- Brain invasion
- Not reported
- Normal/control tissue
- normal healthy human meninges (n=3)
Priority attributes
Peer-reviewed
Publications
- Dunn J, et al. Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism. EBioMedicine, 2019. PMID 30594554 · DOI